CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Aqua Medical›
Library
Aqua Medical

Aqua Medical

Aqua Medical: Innovating GI disease treatment with vapor-based, endoscopic ablation technology.

HQ
Santa Ana, CA, US
Founded
2016
Loading
Overview
Compare
Fundraising
Employees
News
Library

Aqua Medical - Library

Official pages and third-party coverage in one index.

aquaendoscopy.com·15 items across 9 mapped pages · Crawled Sep 24, 2026·

Topics

Publication type

Content origin
Row density

Official pages and third-party coverage in one index

Press

4 pages
  1. Aqua Medical Highlights 100 Insulin Elimination for 12 Months in Patients with Type 2 Diabetes with Its Breakthrough Through the Scope Procedure at Digestive Disease Week Ddw 2026/news/aqua-medical-highlights-100-insulin-elimination-for-12-months-in-patients-with-type-2-diabetes-with-its-breakthrough-through-the-scope-procedure-at-digestive-disease-week-ddw-2026

    PLEASANTON, Calif., May 5, 2026 /PRNewswire/ — Aqua Medical, Inc., a pioneer in Endoscopic Metabolic Restoration (www.aquaendoscopy.com), yesterday announced the presentation of 12-month follow-up outside US clinical data for its proprietary radiofrequency vapor ablation (RFVA) platform at Digestive Disease Week® (DDW) 2026, highlighting the potential of its Proximal Intestinal Mucosal Ablation (PIMA) procedure to deliver durable, procedure-based treatment for type 2 diabetes. Data presented at

  2. Aqua Medical Secures Fda Ide to Study Its Breakthrough Endoscopic Technology for the Treatment of Type 2 Diabetes/news/aqua-medical-secures-fda-ide-to-study-its-breakthrough-endoscopic-technology-for-the-treatment-of-type-2-diabetes

    PLEASANTON, Calif., Nov. 4, 2025 /PRNewswire/ — Aqua Medical, a company advancing Endoscopic Metabolic Restoration for type 2 diabetes, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for its pilot clinical trial of the Proximal Intestinal Mucosal Ablation (PIMA) procedure using the company’s proprietary radiofrequency vapor ablation (RFVA) […]

  3. News/news

    AQUA Medical – News

  4. The 2026 Tag Awards for Medtech Announce Winners Honoring Innovation Across Medtech Life Sciences and Biotech/news/the-2026-tag-awards-for-medtech-announce-winners-honoring-innovation-across-medtech-life-sciences-and-biotech

    Charlotte, NC — APRIL 22, 2026 — The TAG Awards for MedTech, produced by The Aebli Group, is proud to announce the Class of 2026 winners, recognizing companies advancing what is possible across MedTech, Life Sciences, and BioTech. This year’s honorees were selected for solutions that demonstrate strong design, real-world relevance, market value, and the […]

About

1 page
  1. About Us/about-us

    Leadership Team Robert “Bob” Haggerty President/Chief Executive Officer Virender K. Sharma, MD Founder/CMO/Director Scott McGill VP Research & Development Robert “Bob” Haggerty President/Chief Executive Officer Robert “Bob” Haggerty President/Chief Executive Officer Robert “Bob” Haggerty brings more than 35 years of medical device leadership to Aqua Medical, including more than three decades of experience in gastroenterology. […]

Contact

1 page
  1. Contact/contact

    Contact Us Send us a message Mailing Address Aqua Medical, Inc. 6634 Owens Drive Pleasanton, CA 94588

Homepage

2 pages
  1. Homepage/

    Aqua Medical’s through-the-endoscope, 30-minute outpatient treatment represents an intervention to enhance control for individuals with type 2 diabetes.

  2. Homepage/

    Aqua Medical’s through-the-endoscope, 30-minute outpatient treatment represents an intervention to enhance control for individuals with type 2 diabetes.

Privacy

1 page
  1. Privacy Policy/privacy-policy

    Our Privacy Policy Effective date: January 18, 2023 Privacy Notice Aqua Medical, Inc., (hereinafter also referred as: “Aqua Medical”, “we”, “us” or “our) is conducting business within the United States, the United Kingdom, the European Union (EU) and the European Economic Area (EEA) understands the importance of privacy to our customers, visitors, suppliers, business partners, […]

Not yet classified

1 page
  1. aquaendoscopy.com/

    Aqua Medical’s through-the-endoscope, 30-minute outpatient treatment represents an intervention to enhance control for individuals with type 2 diabetes.

Coverage

5 items
  1. Aqua Medical Secures Series B Funding to Advance U.S. Pivotal Trial for Novel Through-the-Scope Type 2 Diabetes Procedureaquaendoscopy.com/news/aqua-medical-secures-series-b-funding-to-advance-u-s-pivotal-trial-for-novel-through-the-scope-type-2-diabetes-procedure/

    Aqua Medical raises a Series B led by Relevance Ventures to advance U.S. studies of its investigational PIMA procedure for Type 2 diabetes. The funding will support completion of the RESTORE-1 pilot study and preparation for a planned U.S. pivotal trial. PIMA is described as a novel through-the-scope procedure.

    Sep 2026 · Aqua MedicalNews article

  2. Aqua Medical Names Bob Haggerty CEO to Take on Type 2 Diabetesaquaendoscopy.com/news/aqua-medical-names-bob-haggerty-ceo-to-take-on-type-2-diabetes/

    Aqua Medical appoints medical device executive Bob Haggerty as president and CEO, effective July 31, 2026. The appointment is framed as part of the company’s effort to take on type 2 diabetes.

    Aug 2026 · Aqua Medical Inc.News article

  3. Aqua Medical Treats First U.S. Patient for Type 2 Diabetes at UNC Health Using Investigational Through-The-Scope Endoscopic Therapyaquaendoscopy.com/news/aqua-medical-treats-first-u-s-patient-for-type-2-diabetes-at-unc-health-using-investigational-through-the-scope-endoscopic-therapy/

    Aqua Medical treats the first U.S. patient in its FDA-authorized IDE trial at UNC Health. The patient receives the investigational PIMA procedure, a through-the-scope endoscopic therapy for type 2 diabetes.

    Jul 2026 · Aqua Medical Inc.News article

  4. Aqua Medical Highlights 100% Insulin Elimination for 12 Months in Patients with Type 2 Diabetes with its Breakthrough Through-the-Scope Procedure at Digestive Disease Week 2026aquaendoscopy.com/news/aqua-medical-highlights-100-insulin-elimination-for-12-months-in-patients-with-type-2-diabetes-with-its-breakthrough-through-the-scope-procedure-at-digestive-disease-week-ddw-2026/

    Aqua Medical presented 12-month clinical follow-up data for its PIMA procedure at Digestive Disease Week 2026. The headline reports 100% insulin elimination for 12 months in patients with type 2 diabetes.

    May 2026 · Aqua Medical Inc.News article